More significantly, an ovarian cancer patient-derived R81T mutation of Sin1 was demonstrated to gain oncogenic capacity by bypassing this negative regulation due to the lack of Sin1-T86 phosphorylation, providing a molecular mechanism for the elevated mTORC2/Akt activation that could potently promote tumorigenesis at least in this cancer patient. This evidence concerns the gene AKT1 and cancer.